cheetah-medical... CHEETAH NICOM™ and Starling™ SV provide continuous, accurate, non-invasive hemodynamic monitoring and empowers volume management in virtually any clinical setting. They are both based on Bioreactance®, a technology that was developed by Cheetah Medical's scientists over years of research and development, followed by extensive testing and validation.
Bioreactance technology begins by placing 4 dual sensors on the patient. The monitor sends a signal at a frequency of 75 kHz into the thorax via the outer portion of the sensors. The known frequency is then received via the inner portion of the sensors from which the monitor compares to the original signal. It will then observe to what extent a time delay, or phase shift, has occurred helping to determine patient fluid responsiveness.
An advantage of bioreactance technology is the signal is only affected by pulsatile flow. The signal is reflected from the base of the aorta back to the sensors.
Pressure, volumetric flow, resistance, capacitance, compliance, velocity, and viscosity are some of the things that contribute to flow. Ultimately there is a relationship to “time” with all of these factors. In short, these factors of pulsatile flow cause a shift in the signal called “phase shift”, but is better understood as a “time delay”.
The received signal is compared to what was sent into the thorax. It determines how much blood had to have been coming out of the left ventricle and into the base of the aorta to cause that specific time delay; this becomes the stroke volume. Because there are ECG leads built into the unique Cheetah Medical sensors, heart rate can be detected. This allows one to obtain Cardiac Output, or HR X SV = CO.
3 фев 2015
